


Allianz Biotechnologie R EUR / DE000A2AMPU5 / A2AMPU / Allianz Gl.Investors

Last 04/18/2024 ¹	Region	Branch	Type of yield	Type
146.01 EUR	Worldwide	Sector Biotechnology	paying dividend	Equity Fund



Risk key figures

SRI	1	2	3	4	5	6	7	
Mountain-View Funds Rating ²							EDA ³	74

Yearly Performance

2023	+3.11%
2022	-5.20%
2021	+10.48%
2020	+17.23%
2019	+34.41%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	0.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Germany	Redemption charge	0.00%	Performance fee	0.00%
Tranch volume	(01/03/2024) EUR 0.324 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(02/28/2023) EUR 295.05 mill.	Dividends		Investment company	
Launch date	11/16/2017	04.03.2024	2.49 EUR	Allianz Gl.Investors Bockenheimer Landstraße 42-44, 60323, Frankfurt am Main Germany https://www.allianzgi.com	
KESt report funds	No	06.03.2023	2.75 EUR		
Business year start	01.01.	02.03.2020	0.06 EUR		
Sustainability type	-	04.03.2019	0.35 EUR		
Fund manager	Chris Chin	05.03.2018	0.19 EUR		

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	-4.52%	+2.18%	-5.10%	-0.41%	+0.56%	+0.78%	+42.96%	+50.59%
Performance p.a.	-	-	-	-0.41%	+0.28%	+0.26%	+7.40%	+6.58%
Sharpe ratio	-2.82	0.03	-1.18	-0.27	-0.18	-0.18	0.15	0.12
Volatility	16.30%	18.40%	17.21%	15.93%	20.31%	20.29%	23.74%	23.40%
Worst month	-	-7.27%	-7.05%	-7.27%	-7.27%	-14.03%	-14.03%	-14.03%
Best month	-	15.49%	15.49%	15.49%	15.49%	15.49%	16.60%	16.60%
Maximum loss	-7.05%	-10.83%	-10.83%	-13.19%	-16.83%	-27.98%	-27.98%	-

Distribution permission

Austria, Germany

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

³ Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

Allianz Biotechnologie R EUR / DE00A2AMPU5 / A2AMPU / Allianz GI.Investors

Investment strategy


We pursue an active management approach aimed at outperforming the benchmark. The benchmark index is used for performance measurement purposes only and not for the purpose of portfolio composition. The majority of the securities included in the Fund are also included in the benchmark index. The fund manager has the flexibility to invest in securities that are not included in the benchmark index. When selecting and weighting the Fund's assets, Fund Management may deviate significantly from the securities included in the benchmark index, as well as their corresponding weightings. Benchmark: NASDAQ Biotechnology Price (in EUR).

Investment goal


The Fund aims to generate long-term capital growth. We invest at least 70% of the Fund's assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund's assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund's assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund's assets may be invested in target funds (UCITS and/or UCI).

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

